AYTU AYTU BIOPHARMA INC revenue, earnings and financials

For the quarter ended March 31, 2026, AYTU BIOPHARMA INC reported revenue of $12.4M (down 32.7% from a year earlier), net income of −$5.62M and diluted EPS of −$0.53; over the last four quarters revenue was $56.6M and net income −$34.1M; for the fiscal year ended June 2025 revenue was $66.4M, up 1.8% on the year before.

AYTU annual revenue and earnings

• Fiscal year ended Jun 2025: revenue $66.4M, gross profit $45.8M, operating income −$7.83M, net income −$13.6M (margin -20.5%), EPS n/a
• Fiscal year ended Jun 2024: revenue $65.2M, gross profit $49.1M, operating income −$1.59M, net income −$15.8M (margin -24.2%), EPS n/a
• Fiscal year ended Jun 2023: revenue $107M, gross profit $66.6M, operating income −$17.1M, net income −$17.1M (margin -15.9%), EPS −$5.11
• Fiscal year ended Jun 2022: revenue $96.7M, gross profit $52.3M, operating income −$110M, net income −$109M (margin -112.5%), EPS −$74.01
• Fiscal year ended Jun 2021: revenue $65.6M, gross profit $29.2M, operating income −$58.9M, net income −$58.3M (margin -88.8%), EPS −$3.48

AYTU quarterly revenue and earnings

• Quarter ended Mar 31, 2026: revenue $12.4M (down 32.7% year over year), net income −$5.62M, EPS −$0.53
• Quarter ended Dec 31, 2025: revenue $15.2M (down 6.5% year over year), net income −$10.6M, EPS −$1.05
• Quarter ended Sep 30, 2025: revenue $13.9M (down 16.2% year over year), net income $1.97M, EPS −$0.08
• Quarter ended Jun 30, 2025 (from the annual report): revenue $15.1M (up 3.7% year over year), net income −$19.9M, EPS n/a
• Quarter ended Mar 31, 2025: revenue $18.5M (up 31.6% year over year), net income $3.99M, EPS $0.21
• Quarter ended Dec 31, 2024: revenue $16.2M (down 13.5% year over year), net income $788K, EPS −$0.26
• Quarter ended Sep 30, 2024: revenue $16.6M (down 7.0% year over year), net income $1.47M, EPS −$0.15
• Quarter ended Jun 30, 2024 (from the annual report): revenue $14.6M (down 52.5% year over year), net income −$4.57M, EPS n/a
• Quarter ended Mar 31, 2024: revenue $14.0M (down 38.3% year over year), net income −$2.89M, EPS −$0.52
• Quarter ended Dec 31, 2023: revenue $18.7M (down 28.7% year over year), net income −$220K, EPS −$0.04
• Quarter ended Sep 30, 2023: revenue $17.8M (down 35.6% year over year), net income −$8.12M, EPS −$1.48
• Quarter ended Jun 30, 2023 (from the annual report): revenue $30.7M (up 12.0% year over year), net income −$2.46M, EPS −$0.75
• Quarter ended Mar 31, 2023: revenue $22.7M (down 6.1% year over year), net income −$7.20M, EPS −$1.93
• Quarter ended Dec 31, 2022: revenue $26.3M (up 13.6% year over year), net income −$6.69M, EPS −$2.15
• Quarter ended Sep 30, 2022: revenue $27.7M (up 26.3% year over year), net income −$701K, EPS −$0.28
• Quarter ended Jun 30, 2022 (from the annual report): revenue $27.4M, net income −$16.1M, EPS −$7.61
• Quarter ended Mar 31, 2022: revenue $24.2M (up 79.5% year over year), net income −$53.3M, EPS −$35.90
• Quarter ended Dec 31, 2021: revenue $23.1M, net income −$11.5M, EPS −$8.74
• Quarter ended Sep 30, 2021: revenue $21.9M, net income −$27.9M, EPS −$21.76
• Quarter ended Mar 31, 2021: revenue $13.5M, net income −$25.5M, EPS −$1.41

AYTU cash flow, buybacks and dividends

• Fiscal year ended Jun 2025: operating cash flow −$1.94M, share buybacks n/a
• Fiscal year ended Jun 2024: operating cash flow −$1.39M, share buybacks n/a
• Fiscal year ended Jun 2023: operating cash flow −$5.13M, share buybacks n/a
• Fiscal year ended Jun 2022: operating cash flow −$28.8M, share buybacks n/a
• Fiscal year ended Jun 2021: operating cash flow −$26.0M, share buybacks n/a

AYTU balance sheet

• Jun 30, 2026: cash $26.3M, total assets $105M, total liabilities n/a, shareholders' equity $35.3M, long-term debt $9.10M
• Mar 31, 2026: cash $26.7M, total assets $112M, total liabilities n/a, shareholders' equity $35.1M, long-term debt $9.55M
• Dec 31, 2025: cash $30.0M, total assets $122M, total liabilities n/a, shareholders' equity $14.2M, long-term debt $10.00M
• Sep 30, 2025: cash $32.6M, total assets $125M, total liabilities n/a, shareholders' equity $23.2M, long-term debt $10.4M
• Jun 30, 2025: cash $31.0M, total assets $124M, total liabilities n/a, shareholders' equity $19.0M, long-term debt $10.9M
• Mar 31, 2025: cash $18.2M, total assets $124M, total liabilities n/a, shareholders' equity $34.9M, long-term debt $9.54M
• Dec 31, 2024: cash $20.4M, total assets $116M, total liabilities n/a, shareholders' equity $30.8M, long-term debt $9.98M
• Sep 30, 2024: cash $20.1M, total assets $116M, total liabilities n/a, shareholders' equity $29.8M, long-term debt $10.4M

What is AYTU's revenue?

AYTU BIOPHARMA INC reported $56.6M of revenue over its last four quarters, through March 31, 2026.

Is AYTU profitable?

No. AYTU BIOPHARMA INC lost $34.1M over the last four quarters.

AYTU ownership and insider trades · All stocks